Patents Assigned to AnGes, Inc.
  • Publication number: 20250090634
    Abstract: Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema.
    Type: Application
    Filed: September 18, 2024
    Publication date: March 20, 2025
    Applicant: AnGes, Inc.
    Inventors: Ryuichi Morishita, Yasufumi Kaneda, Hironori Nakagami, Yukihiro Saito
  • Publication number: 20230330214
    Abstract: Provided is DNA that: encodes a coronavirus (SARS CoV-2) spike protein or a fragment thereof; and has been optimized to partially or fully exhibit a codon included in a DNA sequence.
    Type: Application
    Filed: September 30, 2021
    Publication date: October 19, 2023
    Applicants: OSAKA UNIVERSITY, TAKARA BIO INC., ANGES, INC.
    Inventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Hiroki HAYASHI, Yasunori AMAISHI, Sachiko OKAMOTO, Junichi MINENO, Hisato IKAI, Junko MICHIBATA, Takao KOMATSUNO
  • Patent number: 11453880
    Abstract: Disclosed is a double-stranded oligonucleotide decoy including two transcription factor-binding sites, while keeping its size small. The double-stranded oligonucleotide decoy showing binding affinities for two transcription factors includes a first binding site for a first transcription factor and a second binding site for a second transcription factor. A first strand including the sense strand of the first binding site and a second strand including the sense strand of the second binding site are hybridized to form a double strand in which the sense strand of the first binding site and the sense strand of the second binding site are at least partly hybridized.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 27, 2022
    Assignees: ANGES, INC., GENEDESIGN, INC.
    Inventors: Ryuichi Morishita, Takashi Miyake, Tetsuo Miyake, Takahiro Nakazawa, Makoto Sakaguchi, Satoshi Inoue, Ryoji Ueki
  • Publication number: 20220088141
    Abstract: Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema.
    Type: Application
    Filed: April 26, 2021
    Publication date: March 24, 2022
    Applicant: AnGes, Inc.
    Inventors: Ryuichi Morishita, Yasufumi Kaneda, Hironori Nakagami, Yukihiro Saito
  • Patent number: 10695420
    Abstract: The present invention provides a combination preparation for inducing a specific immune response to an antigenic peptide, which contains (I) the antigenic peptide, and (II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide, into which the antigenic peptide has been inserted or added, wherein said antigenic peptide is inserted in a region of amino acid residues 74-87 or 130-138 of the hepatitis B virus core antigen polypeptide, or added to the N-terminal or C-terminal of the hepatitis B virus core antigen polypeptide, wherein the antigenic peptide of (I) and the expression vector of (II) are substantially simultaneously administered to a subject.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: June 30, 2020
    Assignees: ANGES, INC., OSAKA UNIVERSITY, DS PHARMA ANIMAL HEALTH CO., LTD.
    Inventors: Hironori Nakagami, Ryuichi Morishita, Hiroshi Koriyama, Hideki Tomioka, Kenji Naohara
  • Patent number: 10543261
    Abstract: The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of VEGF and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: January 28, 2020
    Assignees: Osaka University, AnGes, Inc.
    Inventors: Hironori Nakagami, Mariko Kyutoku, Ryuichi Morishita, Hideki Tomioka
  • Publication number: 20190321444
    Abstract: Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema.
    Type: Application
    Filed: January 3, 2019
    Publication date: October 24, 2019
    Applicant: AnGes, Inc.
    Inventors: RYUICHI MORISHITA, Yasufumi Kaneda, Hironori Nakagami, Yukihiro Saito
  • Publication number: 20180298381
    Abstract: Disclosed is a double-stranded oligonucleotide decoy including two transcription factor-binding sites, while keeping its size small. The double-stranded oligonucleotide decoy showing binding affinities for two transcription factors includes a first binding site for a first transcription factor and a second binding site for a second transcription factor. A first strand including the sense strand of the first binding site and a second strand including the sense strand of the second binding site are hybridized to form a double strand in which the sense strand of the first binding site and the sense strand of the second binding site are at least partly hybridized.
    Type: Application
    Filed: September 9, 2016
    Publication date: October 18, 2018
    Applicants: AnGes, Inc., GeneDesign, Inc.
    Inventors: Ryuichi MORISHITA, Takashi MIYAKE, Tetsuo MIYAKE, Takahiro NAKAZAWA, Makoto SAKAGUCHI, Satoshi INOUE, Ryoji UEKI
  • Patent number: 9913886
    Abstract: The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: March 13, 2018
    Assignee: AnGes, Inc.
    Inventors: Mariko Kyutoku, Hironori Nakagami, Hiroshi Koriyama, Futoshi Nakagami, Ryuichi Morishita